A prespecified FLOW analysis found once-weekly semaglutide 1 mg lowered the risk of heart failure events or cardiovascular death in adults with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
Secondary analysis of the SELECT trial finds semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes, with much of the non-cardiovascular benefit driven by fewer infectious and COVID-19-related deaths. PICO summary and expert commentary.
A prespecified pooled secondary analysis of the STEP-HFpEF trials found semaglutide improved symptoms, weight, and exercise capacity consistently across baseline C-reactive protein strata and lowered CRP regardless of weight loss. PICO summary and expert commentary.
A secondary analysis of the pooled STEP-HFpEF trials found semaglutide improved heart-failure symptoms more in obesity-related HFpEF patients with a history of atrial fibrillation than in those without. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found once-weekly semaglutide 2.4 mg attenuated left atrial and right ventricular remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
A phase 2b randomized trial of the GLP-1/glucagon dual agonist cotadutide in type 2 diabetes and CKD, with dose-dependent reductions in albuminuria at week 14. PICO summary and expert commentary.
A single-centre RCT (n=180) testing an integrated cloud data platform with dietary management and education videos against routine care in type 2 diabetes, with HbA1c lower at 12 weeks. PICO summary and expert commentary.
A post hoc analysis of the SUSTAIN 6 trial reports that once-weekly semaglutide was associated with lower odds of developing diabetic kidney disease in adults with type 2 diabetes who had no kidney disease at baseline. PICO summary and expert commentary.
A post-hoc pooled analysis of four semaglutide trials found a lower risk of cardiovascular death or worsening heart failure in patients with HFpEF, though cardiovascular death alone was not reduced. PICO summary and expert commentary.
A prespecified secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials examining whether semaglutide 2.4 mg benefits in obesity-related HFpEF differ by sex. PICO summary and expert commentary.